| Bioactivity | Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways[1]. |
| Invitro | Akt/NF-κB/MAPK-IN-1 (compound 2m) （0-20 μM，24 小时）在 LPS (10 ng/mL) 诱导的 RAW264.7 细胞中，可显著降低 TNF-α、IL-1β、IL-6 和 PGE2 的水平，下调 iNOS 和 COX-2 的表达[1]。Akt/NF-κB/MAPK-IN-1（0-20 μM，24 小时）可阻断 LPS 诱导的 RAW264.7 细胞中 p38、ERK 和 JNK 的磷酸化[1]。 0 --> Akt/NF-κB/MAPK-IN-1 相关抗体: |
| In Vivo | Akt/NF-κB/MAPK-IN-1 (compound 2m) (10-20mg /kg, 灌胃，连续7天) 可减轻 LPS 诱导的小鼠炎症性疾病[1]。 Animal Model: |
| Name | Akt/NF-κB/MAPK-IN-1 |
| Formula | C38H56N2O4 |
| Molar Mass | 604.86 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li X, et al. Design, synthesis and evaluation of ursodeoxycholic acid-cinnamic acid hybrids as potential anti-inflammatory agents by inhibiting Akt/NF-κB and MAPK signaling pathways. Eur J Med Chem. 2023 Aug 31;260:115785. |